ALG advised GH Research plc on its $117.5m underwritten public offering of ordinary shares

ALG is pleased to have advised GH Research plc on its $117.5m underwritten public offering of ordinary shares. GH Research is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression. The offering is another example of ALG’s market-leading ECM practice delivering complex and significant cross-border capital raising deals. Congratulations to all of the GH Research team.

The ALG team was led by Corporate and ECM partner, Alan Casey, with Conor Maginn and Gráinne Roche. The team collaborated with tax colleagues Amelia O'Beirne and Cian Ryan.

Date published: 30 April 2026